Effects of angiotensin III and angiotensin IV on pentylenetetrazol seizure susceptibility (threshold and kindling): interaction with adenosine A1 receptors

Tchekalarova, Jana; Kambourova, T; Georgiev, Vasil

doi:10.1016/s0361-9230(01)00568-8

Cited by 34 publications

(20 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Exogenous administration of AngIV has been shown to increase cerebral microcirculation (Naveri et al, 1994;Kramar et al, 1997;Kramar et al, 1998;Lanckmans et al, 2007a,b). In terms of function, intracranially administered AngIV and its functional analogs facilitate memory in rodent behavior models (Braszko et al, 1988;Wright et al, 1993;Tchekalarova et al, 2001;Lee et al, 2003). AngIV also facilitates reversal of memory shortfalls produced by scopolamine, mecamylamine, abusive alcohol dose, ischemia, as well as by disruption of the perforant path in the hippocampus (Borawska et al, 1989;Wright et al, 1996;Pederson et al, 1998;Albiston et al, 2004a;Olson et al, 2004).…”

Section: E Distribution Of the Of Angiv Binding Sitesmentioning

confidence: 99%

“…AngIV also facilitates reversal of memory shortfalls produced by scopolamine, mecamylamine, abusive alcohol dose, ischemia, as well as by disruption of the perforant path in the hippocampus (Borawska et al, 1989;Wright et al, 1996;Pederson et al, 1998;Albiston et al, 2004a;Olson et al, 2004). AngIV enhances neuronal long-term potentiation in vitro and in vivo (Kramar et al, 2001;Wayner et al, 2001) as well as attenuates PTZinduced seizures (Tchekalarova et al, 2001;Stragier et al, 2006) and protects against cerebral ischemia (Faure et al, 2006a(Faure et al, ,b, 2008. It is reported that in peripheral tissue AngIV administration increases renal blood flow that was blocked by antagonist divalinal-AngIV (Coleman et al, 1998;Hamilton et al, 2001).…”

Section: E Distribution Of the Of Angiv Binding Sitesmentioning

confidence: 99%

See 1 more Smart Citation

International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli

et al. 2015

View full text Add to dashboard Cite

Section: E Distribution Of the Of Angiv Binding Sitesmentioning

confidence: 99%

Section: E Distribution Of the Of Angiv Binding Sitesmentioning

confidence: 99%

International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli

et al. 2015

View full text Add to dashboard Cite

“…Interestingly, the selective adenosine A(1) receptor agonist cyclopentyladenosine (CPA) attenuates angiotensin-IV-induced memory enhancement (Tchekalarova et al 2001b) indicating an interaction of angiotensin IV with adenosine. This interaction seems to be context-specific since, in this experimental design, adenosine A1 receptor agonists attenuate angiotensin-IV-induced effects, whereas adenosin A1 receptor agonists potentiate the effects of angiotensin IV on seizure threshold and kindling (Tchekalarova et al 2001a).…”

Section: Effects Of Angiotensin IV On Behaviormentioning

confidence: 94%

Angiotensin IV in the central nervous system

Halbach

2003

Cell and Tissue Research

View full text Add to dashboard Cite

The mammalian brain harbors a renin-angiotensin system (RAS), which is independent from the peripheral RAS. Angiotensin II is a well-studied member of the RAS and exerts most of the known angiotensin-mediated effects on fluid and electrolyte homeostasis, autonomic activity, neuroendocrine regulation, and behavior. This review summarizes a mass of compelling new evidence for the biological role of an active (3-8) fragment of angiotensin II, named angiotensin IV. Angiotensin IV binds to a widely distributed binding site in the brain, but which is different from the known angiotensin II receptors AT1 and AT2. Angiotensin IV has been implicated in a number of physiological actions, including the regulation of blood flow, the modulation of exploratory behavior, and processes attributed to learning and memory. Furthermore, angiotensin IV may also be involved in neuronal development. Collectively, the available evidence suggests that angiotensin IV is a potent neuropeptide, involved in a broad range of brain functions.

show abstract

“…The pro-convulsive effect of AngII could be related to its inhibitory action on GABA release [252] and its excitatory action on hippocampal pyrami- dal cells [240]. The interaction of AngII with other neuromodulator systems, particularly adenosine has also been suggested [253]. Given the recent description of distribution of nucleosides in human [254,255], the interaction of AngII with nucleosides promises interesting findings in the future.…”

Section: Angiotensinsmentioning

confidence: 99%

Receptors of Peptides as Therapeutic Targets in Epilepsy Research

Dobolyi¹,

Kékesi²,

Juhász³

et al. 2014

CMC

View full text Add to dashboard Cite

Neuropeptides are signaling molecules participating in the modulation of synaptic transmission. Neuropeptides are stored in dense core synaptic vesicles, the release of which requires profound excitation. Only in the extracellular space, neuropeptides act on G-protein coupled receptors to exert a relatively slow action both pre-and postsynaptically. Consequently, neuropeptide modulators are ideal candidates to influence epileptic tissue overexcited during seizures. Indeed, a number of neuropeptides have been implicated in epilepsy and many of them are considered to have endogenous neuroprotective actions. Neuropeptides, present in the hippocampus, the most frequent focus of seizures in temporal lobe epilepsy, received the largest attention as potential anti-epileptic substances. Hippocampal neuropeptides, somatostatin, neuropeptide Y, galanin, dynorphin, enkephalin, substance P, cholecystokinin, vasoactive intestinal polypeptide, and some neuropeptides, which are also hormones such as ghrelin, angiotensins, corticotropin-releasing hormone, adrenocorticotropin, thyrotropin-releasing hormone, oxytocin and vasopressin involved in epilepsy are discussed in the review article. Oral application of neuropeptides as drugs is typically not efficient because of low bioavailability: rapid degradation and insufficient penetration through the blood-brain barrier. Recent progress in the development of non-peptide agonists and antagonists of neuropeptide receptors as well as gene therapeutic approaches leading to the local production of neuropeptides within the central nervous system will also be discussed.

show abstract

Effects of angiotensin III and angiotensin IV on pentylenetetrazol seizure susceptibility (threshold and kindling): interaction with adenosine A1 receptors

Cited by 34 publications

References 21 publications

International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli

International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli

Angiotensin IV in the central nervous system

Receptors of Peptides as Therapeutic Targets in Epilepsy Research

Contact Info

Product

Resources

About